Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Comfovita is a branded generic pharmaceutical product developed by Grand Medical Group, consisting of a combination of neurotropic B vitamins: thiamine (B1), pyridoxine (B6), and cyanocobalamin (B12). It is primarily indicated for the treatment of various neurological conditions, including neuritis, neuralgia, and polyneuropathy (such as diabetic or alcoholic neuropathy). The vitamins in Comfovita act as essential coenzymes in metabolic processes within the central and peripheral nervous systems, supporting nerve regeneration, myelin sheath formation, and neurotransmitter synthesis. Thiamine facilitates carbohydrate metabolism and nerve impulse conduction; pyridoxine is involved in the synthesis of neurotransmitters like dopamine and serotonin; and cyanocobalamin is critical for the synthesis of myelin and the maturation of red blood cells. The product is typically available as a solution for intramuscular injection or as oral tablets.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiamine + pyridoxine + cyanocobalamin.